A5090339215- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Mathematical Biology Tumor Growth
- Cancer Research and Treatments
- Single-cell and spatial transcriptomics
- Cellular Mechanics and Interactions
- Protein Degradation and Inhibitors
- 3D Printing in Biomedical Research
- Cell Image Analysis Techniques
- Cancer Cells and Metastasis
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- MicroRNA in disease regulation
- Extracellular vesicles in disease
- Cancer Mechanisms and Therapy
- Immune cells in cancer
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
Erasmus MC Cancer Institute
2022-2023
Erasmus MC
2019-2023
Codarts Rotterdam
2022
New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts subtype patients based on molecular profiles have failed direct treatment strategies. We hypothesised that interrogation of the GBM tumour microenvironment (TME) and identification novel TME-specific subtypes could inform new immunotherapy strategies.A refined validated cell population (MCP) counter method was applied >800 patient tumours (GBM-MCP-counter). Specifically, partition around...
Abstract Background Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of situ microenvironment affects clinically-predictive value this model. We implemented a GSC monolayer system investigate - vitro molecular correspondence and relationship between patient response temozolomide (TMZ). Methods DNA/RNA-sequencing was performed on 56 glioblastoma tissues 19 derived cultures. Sensitivity...
Glioblastoma (GBM) is an aggressive brain cancer that typically results in death the first 15 months after diagnosis. There have been limited advances finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 Long LTS).Patients were selected from in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age < 70 years old; Stupp...
Glioblastoma is the deadliest brain cancer. One of main reasons for poor outcome resides in therapy resistance, which adds additional challenges finding an effective treatment. Small protein kinase inhibitors are molecules that have become widely studied cancer treatments, including glioblastoma. However, none these drugs demonstrated a therapeutic activity or brought more benefit compared to current standard procedure clinical trials. Hence, understanding limited efficacy and drug...
Abstract Glioblastoma (GBM) is an aggressive brain cancer that typically results in death the first 15 months after diagnosis. There have been limited advances finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤9 months, Short term survivors, STS) and long survival (≥36 Long LTS). Patients were selected from in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score >70; age <70 years...
Abstract Background Radiation therapy and chemotherapy using Temozolomide are the standard adjuvant treatments for patients with glioblastoma. Despite maximal treatment prognosis is still poor largely due to emergence of resistance. This resistance closely linked widely recognized inter- intra-tumoral heterogeneity in glioblastoma, although underlying mechanisms not yet fully understood. study aims investigate diverse molecular involved temozolomide Methods To induce resistance, we subjected...
Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma. Despite treatment, prognosis still poor largely due to emergence of resistance. This resistance closely linked widely recognized inter- and intra-tumoral heterogeneity in glioblastoma, although underlying mechanisms are not yet fully understood. To induce resistance, we subjected 21 patient-derived glioblastoma cell cultures Temozolomide a period up 90 days. Prior cells’ molecular characteristics were...
Abstract BACKGROUND Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of situ microenvironment affects clinically-predictive value this model. We implemented a GSC monolayer system investigate situ-in vitro molecular correspondence and relationship between patient response temozolomide (TMZ). METHODS DNA RNA-sequencing was performed on 56 glioblastoma tissues 19 derived cultures....
Abstract BACKGROUND Glioblastoma multiforme is the most common and aggressive brain tumor in adults, with an average overall survival of 14 months. Current standard care consists resection followed by radiotherapy concomitant temozolomide adjuvant temozolomide. However, glioblastoma recurs all patients. The causes reside enhanced invasiveness resistance to treatment, giving a clear indication that recurrent resistant biology must be understood better order achieve future treatment strategies...
Abstract Background: The brain tumor glioblastoma (GBM) is one of the most aggressive forms cancer. dismal prognosis these patients, with a median survival less than 15 months despite maximal therapy makes need for new therapeutic approaches urgent. Clinical trials employing oncolytic viruses (OVs) have shown encouraging results, however, it appears that each OV only small group patients responds to treatment. As inter- and intra-tumoral heterogeneity hallmark GBM, we hypothesized fresh...
ABSTRACT Glioblastoma is the deadliest brain cancer. One of main reasons for poor outcome resides in therapy resistance, which adds additional challenges finding an effective treatment. Small protein kinase inhibitors are molecules that have become widely studied cancer treatments, including glioblastoma. However, none these drugs demonstrated a therapeutic activity or brought more benefit compared to current standard procedure clinical trials. Hence, understanding limited efficacy and drug...
Abstract INTRODUCTION The search for effective therapies gliomas is progressively moving towards patient-specific medicine. In order to test patient-tailored therapies, it vital develop protocols reliable establishment of patient-derived glioma cultures. We present a method culture establishment, with 95% success rate in 114 consecutive high-grade samples. METHODS Cell cultures were established from either traditionally-resected tumor tissue or ultrasonic surgical aspirator (CUSA) derived...